Last reviewed · How we verify
NCT05984303
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1b)
Phase 1 trial testing Human Umbilical Cord-derived Mesenchymal Stem Cells in Decompensated Cirrhosis in 6 participants. Status unknown.
30 August 2024
Quick facts
| Lead sponsor | Beijing 302 Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 30 August 2023 |
| Primary completion | 30 August 2024 |
| Estimated completion | 30 August 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Human Umbilical Cord-derived Mesenchymal Stem Cells
Conditions studied
- Decompensated Cirrhosis — all drugs for Decompensated Cirrhosis →
Sponsor
Beijing 302 Hospital
Who can join
Adults 18 to 75, any sex, with Decompensated Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial is a Phase 1, multiple administration, dose-escalasion clinical trial of human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis. The primary objective of this study is to assess the safety of intravenous infusion of human umbilical cord-derived mesenchymal stem cells in patients with decompensated cirrhosis.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.
Taherian M, Bayati P, Mojtabavi N. · · 2024 · cited 18× · PMID 38886859 · DOI 10.1186/s13287-024-03782-5 -
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials.
Huang WC, Li YC, Chen PX, Ma KS, et al · · 2025 · cited 14× · PMID 39762946 · DOI 10.1186/s13287-024-04127-y -
Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights.
Shi L, Zhang Z, Mei S, Wang Z, et al · · 2025 · cited 7× · PMID 40721581 · DOI 10.1038/s41392-025-02318-4 -
Cell therapy for end-stage liver disease: Current state and clinical challenge.
Zhang L, Deng Y, Bai X, Wei X, et al · · 2024 · cited 5× · PMID 39602326 · DOI 10.1097/cm9.0000000000003332 -
From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy.
Bozorgi V, Babaahmadi M, Salehi M, Vafaeimanesh J, et al · · 2025 · cited 4× · PMID 40764597 · DOI 10.1186/s13287-025-04535-8 -
Materiobiology-guided regulation of mesenchymal stromal cell fate for aging-related diseases: From basic parameter design to clinical application.
Feng Y, Qiu Y, Zhang S, Dai K, et al · · 2026 · PMID 41799951 · DOI 10.1016/j.bioactmat.2026.02.034 -
Stem Cell Therapy for Inflammatory Diseases: Progress, Challenges, and Future Directions.
Wu C, Jin ZP, Weng SQ, Zhu JM, et al · · 2026 · PMID 41640457 · DOI 10.1002/mco2.70616 -
Modular mastery of inflammation: umbilical cord mesenchymal stem cells as a therapeutic frontier.
Yin L, Sun CY, Chen GL, Xiang Z, et al · · 2025 · PMID 41488628 · DOI 10.3389/fimmu.2025.1721947
Verify or expand the search:
- PubMed search for NCT05984303
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Human Umbilical Cord-derived Mesenchymal Stem Cells
Trials testing the same drug.
- NCT05227846 — Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1) · Phase 1 · unknown
Other recruiting trials for Decompensated Cirrhosis
Currently open trials in the same condition.
- NCT06823713 — RTX001 Autologous Engineered Macrophages for Liver Cirrhosis · Phase 1, PHASE2 · recruiting
- NCT05224960 — Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2) · Phase 2 · recruiting
- NCT06396897 — Hospital @ Home Model of Care for Cirrhosis · NA · recruiting
- NCT06374511 — Prospective Cohort Study of Complications and Outcomes in Cirrhosis · recruiting
- NCT06134544 — Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis · NA · recruiting
Other Beijing 302 Hospital trials
Trials by the same sponsor.
- NCT07514832 — VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial · Phase 2 · recruiting
- NCT07297173 — Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia · Phase 1 · recruiting
- NCT06556862 — Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor · Phase 2 · not yet recruiting
- NCT07106658 — TEAS for Variceal Bleeding Endoscopy in Cirrhosis · NA · completed
- NCT06926647 — A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05984303 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing 302 Hospital
- Last refreshed: 9 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05984303.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing